Skip to main content
  • Poster presentation
  • Open access
  • Published:

In vivo diagnosis and therapy of Alzheimer's disease

Alzheimer's disease (AD) is a progessive neurodegenerative disorder. The 'amyloid cascade hypothesis' assigns the amyloid-beta-peptide (Abeta) a central role in the pathogenesis of Alzheimer's disease. We searched for peptides consisting of the D-enantiomers of amino acids (D-peptides) that bind to Abeta (1–42). D-peptides are thought to be protease resistant and less immunogenic than the respective L-enantiomers and can be identified by mirror image phage display. We carried out a screening of a randomized 12 mer peptide library and identified a dominating D-peptide (D-pep). In vitro experiments verified binding of D-pep to naturally occuring Abeta and showed positive influence of D-pep on Abeta cytotoxicity. In vivo experiments in transgenic mice suggest D-pep to cross the blood-brain-barrier and to reduce Abeta loads in the living brain.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Wiesehan, K., van Groen, T., Linke, R.P. et al. In vivo diagnosis and therapy of Alzheimer's disease. BMC Neurosci 8 (Suppl 1), P19 (2007).

Download citation

  • Published:

  • DOI: